U.S. Metals and Mining Stock News

NYSE:JPM
NYSE:JPMBanks

Todd Combs Joins JPMorgan Chase As Investors Weigh Valuation And Returns

Todd Combs, former Berkshire Hathaway investment manager and CEO of Geico, has taken on a senior investment leadership role at NYSE:JPM. Combs, known for his work alongside Warren Buffett, is now directly managing investments for Jamie Dimon at JPMorgan Chase. For anyone tracking NYSE:JPM, this move relates to how the bank is approaching long term capital allocation and investment oversight. Large global banks have been sharpening their focus on fee based businesses and asset management,...
NasdaqGS:DKNG
NasdaqGS:DKNGHospitality

DraftKings Lawsuit Puts Addictive Design And Valuation Gap In Focus

Public Health Advocacy Institute has filed a landmark product liability lawsuit naming DraftKings as a primary defendant, alleging its online betting platform is designed to encourage compulsive gambling. The complaint targets microbetting features, personalized promotions, and AI driven engagement tools as addictive product elements rather than just marketing choices. FanDuel, Genius Sports, and the NFL are also named, bringing league partnerships and data providers directly into the legal...
NYSE:OMF
NYSE:OMFConsumer Finance

AM Best Rating Affirmation Supports OneMain Insurance Strength And Investor Focus

AM Best affirmed the credit ratings and outlook for OneMain Holdings’ insurance subsidiaries, reinforcing its view of their financial strength. The decision reflects AM Best’s current assessment of the subsidiaries’ balance sheet quality, risk management and operating performance. For investors watching OneMain Holdings (NYSE:OMF), this rating affirmation comes alongside a mixed share price record. The stock closed at $53.05, with a 4.0% gain over the past week offsetting a 3.9% decline...
NYSE:LW
NYSE:LWFood

Has The Recent Share Price Slump Created An Opportunity In Lamb Weston Holdings (LW)?

If you are wondering whether Lamb Weston Holdings' current share price reflects its underlying value, this article walks through the key signals you can use to judge that for yourself. The stock most recently closed at US$40.83, with returns of 0.5% over 7 days, a 14.9% decline over 30 days, a 3.5% decline year to date and a 22.1% decline over 1 year, alongside a 57.8% decline over 3 years and a 42.9% decline over 5 years. These moves have kept Lamb Weston on the radar for investors looking...
NYSE:CRK
NYSE:CRKOil and Gas

Will Hosting the Texas Gas Power Hub with NextEra Reshape Comstock Resources' (CRK) Western Haynesville Narrative?

Comstock Resources announced that its Western Haynesville operations in Texas were selected in March 2026 to host the Texas Natural Gas-Fired Power Generation Hub, a U.S.-Japan joint project to be built and operated by NextEra Energy under Japan’s very large US$550 billion investment commitment. This collaboration positions Comstock near the center of a major new demand source for Western Haynesville gas, potentially reshaping its role in U.S. energy infrastructure. We’ll now examine how...
NYSE:BKU
NYSE:BKUBanks

Stronger Quarter And Higher Dividend Might Change The Case For Investing In BankUnited (BKU)

BankUnited’s board has approved a quarterly cash dividend of US$0.33 per common share, a 6% increase from US$0.31, payable on April 30, 2026, to shareholders of record on April 10, 2026. This dividend increase, following a quarter in which BankUnited’s revenue and net interest income exceeded analyst expectations, highlights management’s confidence in the bank’s financial position and its emphasis on cash returns to shareholders. We’ll now examine how the stronger quarter and higher dividend...
NasdaqGS:BNTX
NasdaqGS:BNTXBiotechs

BioNTech (NasdaqGS:BNTX) Valuation Check After New Lung Cancer Data Highlights Oncology Pipeline Progress

Clinical data spotlight raises questions for BioNTech (NasdaqGS:BNTX) investors BioNTech (NasdaqGS:BNTX) has put its oncology ambitions in focus after presenting fresh lung cancer data at the European Lung Cancer Congress in Copenhagen, covering late stage immunomodulators and antibody drug conjugates. See our latest analysis for BioNTech. Despite the positive lung cancer updates and a series of conference appearances in March, BioNTech’s recent momentum has been weak, with a 1 month share...
NYSE:MTZ
NYSE:MTZConstruction

Assessing MasTec (MTZ) Valuation After Record Backlog And 2026 Growth Guidance

Backlog-driven interest in MasTec MasTec (MTZ) is drawing investor attention after reporting a record 18 month backlog of US$19b spanning communications, pipeline infrastructure, clean energy and power delivery, along with guidance for revenue and adjusted EBITDA growth in 2026. See our latest analysis for MasTec. Despite a 5.2% 1 day share price decline to US$306.74, MasTec’s momentum has been strong, with a 36.69% 90 day share price return and a very large 1 year total shareholder return of...
NasdaqGS:CRWV
NasdaqGS:CRWVIT

CoreWeave Zonos Deal Tests AI Cloud For Real Time Commerce Workloads

CoreWeave (NasdaqGS:CRWV) has secured Zonos as a major client for its AI cloud infrastructure. Zonos plans to use CoreWeave to power real-time compliance, duty, tax, and international checkout services for global commerce. The partnership underscores demand for low latency, scalable AI infrastructure in cross border e-commerce workflows. For investors tracking CoreWeave at a share price of $80.45, this agreement with Zonos adds another real world workload to its AI cloud footprint. The...
NasdaqGS:COLL
NasdaqGS:COLLPharmaceuticals

Is It Time To Reassess Collegium Pharmaceutical (COLL) After The Recent Share Price Pullback?

If you are wondering whether Collegium Pharmaceutical's current share price reflects its real worth, this breakdown will help you see what the numbers are actually saying about value. The stock closed at US$33.42, with returns of 13.1% over 1 year and 37.1% over 3 years, but a 26.0% decline over 30 days and 26.6% decline year to date may have changed how investors think about its risk and reward profile. Recent coverage has focused on Collegium Pharmaceutical in the context of its share...
NYSE:MA
NYSE:MADiversified Financial

Is It Time To Reconsider Mastercard (MA) Around US$500 After Mixed Multi Year Returns

Wondering if Mastercard at around US$500 a share is still a quality name at a fair price, or if you would be overpaying for growth that may already be reflected in the stock. The share price closed at US$500.75, with a 2.0% return over the last 7 days, 0.6% over the last 30 days, a year-to-date return of an 11.1% decline, a 9.7% decline over 1 year, and a 41.8% return over both 3 and 5 years. These mixed returns can reflect shifting views on growth potential and risk, with some investors...
NasdaqCM:PCT
NasdaqCM:PCTChemicals

Is PureCycle (PCT) Using EU Grant-Funded ASTRA PP Plant To Recast Its European Growth Narrative?

PureCycle Technologies recently signed a €40 million Innovation Fund grant agreement with the EU’s CINEA to build its ‘ASTRA PP’ polypropylene dissolution recycling facility in Belgium’s Port of Antwerp-Bruges, targeting annual production of 59,000 tonnes of PureFive resin and supporting EU circularity and decarbonization goals. The project is intended to help European customers meet recycled content rules in packaging and end-of-life vehicles, positioning PureCycle as a local supplier of...
NYSE:PVH
NYSE:PVHLuxury

PVH (PVH) Valuation Check As Bylaw Change Expands Shareholder Power On Special Meetings

Why PVH’s bylaw change matters for shareholders PVH (PVH) has amended its bylaws, cutting the ownership threshold needed for shareholders to call a special meeting to 25% of outstanding common stock. This change increases the potential influence of shareholders. See our latest analysis for PVH. PVH’s share price is US$66.45, with a 7 day share price return of 3.83% after a softer 30 and 90 day patch and a 5 year total shareholder return decline of 33.65%. This suggests longer term momentum...
NYSE:DRD
NYSE:DRDMetals and Mining

How DRDGOLD’s FTSE All-World Index Inclusion Will Impact DRDGOLD (DRD) Investors

DRDGOLD Limited (JSE:DRD) was recently added to the FTSE All-World Index (USD), broadening its representation in a widely followed global benchmark. This index inclusion can be material for DRDGOLD because it often attracts incremental demand from index-tracking funds and benchmark-aware institutional investors. We will now explore how DRDGOLD’s entry into the FTSE All-World Index may reshape its investment narrative for existing and prospective shareholders. AI is about to change...
NYSE:SLVM
NYSE:SLVMForestry

A Look At Sylvamo (SLVM) Valuation After Recent Share Price Weakness

Sylvamo (SLVM) has drawn investor attention after a choppy stretch for the share price, with the stock showing a decline of about 13% over the past month and a decline of nearly 18% over the past three months. See our latest analysis for Sylvamo. At a share price of about $40.30, Sylvamo’s recent 7 day share price return of 3.95% contrasts with a 30 day share price return showing a 12.88% decline and a 1 year total shareholder return showing a 37.54% loss, which points to fading momentum as...
NYSE:KTB
NYSE:KTBLuxury

A Look At Kontoor Brands (KTB) Valuation As Wrangler Dr. Scholl’s Capsule Targets Festival Shoppers

Kontoor Brands (KTB) is back in focus after Wrangler partnered with Dr. Scholl’s Shoes on a limited-edition capsule that blends Western themed footwear with a co-branded denim jacket aimed at festival season shoppers. See our latest analysis for Kontoor Brands. Despite the recent brand collaborations, Kontoor Brands’ 1-day share price return of 3.15% and 7-day share price return of 2.43% sit against a 90-day share price return of 7.03% and a 5-year total shareholder return of 64.50%. This...
NasdaqCM:TGTX
NasdaqCM:TGTXBiotechs

A Look At TG Therapeutics (TGTX) Valuation After Its New US$750m Credit Facility With Blue Owl

Why TG Therapeutics’ new credit facility matters for shareholders TG Therapeutics (TGTX) shares are reacting to a fresh financing move after the company entered a new five year, US$750 million senior secured credit facility with funds managed by Blue Owl Capital. For you as a shareholder or potential investor, the key points are the repayment of the prior US$250 million facility, a net US$500 million in non dilutive capital, and access to as much as US$1 billion in total debt capacity at the...
NYSE:XOM
NYSE:XOMOil and Gas

Exxon Mobil (XOM) Valuation Check As Strait Of Hormuz Closure Lifts Oil Prices

The closure of the Strait of Hormuz and the resulting oil supply shock have pushed Exxon Mobil (XOM) into sharper focus for investors, as the stock trades near US$165 with strong recent returns. See our latest analysis for Exxon Mobil. The recent 1-day share price return of 1.33% and 7-day share price return of 4.60% add to a strong 30-day move of 10.83%. The 1-year total shareholder return of 45.15% and 5-year total shareholder return of 249.11% point to momentum that has built steadily...
NYSE:FDS
NYSE:FDSCapital Markets

Is FactSet's New AI Document Search Quietly Redefining FDS's Competitive Moat in Financial Data?

FactSet Research Systems has expanded its artificial intelligence capabilities by rolling out its AI-enabled Document Search in broad beta to over 85,000 users, enabling faster, source-linked analysis of transcripts, earnings calls, news, filings, and other unstructured data. This move further integrates FactSet’s LLM-powered tools, including prior ChatGPT and Claude connections, into a unified, multi-interface platform focused on auditable, compliance-aware workflows for financial...
NasdaqGS:GLNG
NasdaqGS:GLNGOil and Gas

Golar LNG Review Weighs Sale Options Against Valuation Gap And Momentum

Golar LNG (NasdaqGS:GLNG) has launched a formal review of options for the business, including a possible sale, merger, asset divestitures, or changes to its corporate structure. The company has appointed Goldman Sachs as financial advisor to support this process. The review aims to assess ways to accelerate growth initiatives and evaluate how the current structure supports long term objectives. For investors watching Golar LNG at a share price of $54.06, the timing of this review follows a...
NYSE:PAYC
NYSE:PAYCProfessional Services

Paycom Awards Highlight Product Strength Workplace Culture And Investor Narrative

Paycom Software (NYSE:PAYC) has been named best software in multiple categories in G2’s Spring 2026 Grid Reports, based on customer reviews. The company was also recognized as a 2026 Platinum Employer on the inaugural Where You Work Matters List. Paycom is reportedly the only firm in its sector to receive the Platinum Employer distinction. Paycom focuses on HR and payroll software, so third party recognition of product quality and customer satisfaction can matter for buyers comparing...
NYSE:BORR
NYSE:BORREnergy Services

Borr Drilling Expands Mexican Presence With Joint Venture Rig Acquisition

Borr Drilling (NYSE:BORR) has agreed to acquire five premium jack-up rigs in Mexico through a new 50/50 joint venture with its long-term partner. The deal uses seller’s credit and a shared ownership structure, and is framed as a meaningful expansion of the company’s fleet in the Mexican offshore drilling market. The transaction introduces a mix of rig designs and increases the company’s exposure to regional activity, while using a different approach to financing future growth. Borr Drilling...
NasdaqGM:NAMS
NasdaqGM:NAMSBiotechs

NewAmsterdam Pharma (NAMS) Valuation Check As Obicetrapib Data Lineup Targets ACC 2026 Attention

Obicetrapib data presentations set to spotlight NewAmsterdam Pharma NewAmsterdam Pharma (NAMS) is drawing attention after announcing multiple data presentations for its oral CETP inhibitor obicetrapib at ACC.26, covering efficacy, kidney function, pooled Phase 3 safety, and LDL particle related cardiovascular outcomes. See our latest analysis for NewAmsterdam Pharma. NewAmsterdam Pharma’s share price has pulled back recently, with a 30 day share price return of 13.22% decline and a year to...
NasdaqGS:ATAT
NasdaqGS:ATATHospitality

Why Atour Lifestyle Holdings (ATAT) Is Down 5.1% After Strong 2025 Results And 2026 Growth Guidance

In March 2026, Atour Lifestyle Holdings reported past fourth-quarter 2025 revenue of CNY 2,787.83 million and net income of CNY 480.34 million, alongside full-year 2025 revenue of CNY 9,790.16 million and net income of CNY 1,620.99 million, while completing a US$46.00 million buyback of 1,250,987 shares. The company also issued guidance for 2026 calling for total net revenue growth of 20% to 24% versus 2025, highlighting management’s confidence in its expansion and earnings profile. Against...